← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Other immunostimulants
motixafortide
L03AX23
Forms & Strengths
- Injectable solution: 1.2 mg/mL in a single-dose vial
Adult Dosing
- Multiple myeloma: 1.25 mg/kg subcutaneously approximately 10 to 14 hours prior to initiation of apheresis, in combination with G-CSF
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
Mechanism of Action
- Selective inhibitor of the C-X-C chemokine receptor type 4 (CXCR4), blocking binding of its ligand SDF-1a (CXCL12), leading to mobilization of hematopoietic stem cells and progenitor cells from the bone marrow into the peripheral circulation
Contraindications
- Known hypersensitivity to motixafortide or its components
Adverse Reactions
- Injection site reactions (pain, erythema, pruritus)
- Pruritus
- Flushing
- Nasopharyngitis
- Dizziness
- Vomiting
- Pyrexia
Drug Interactions
- No formal clinical drug-drug interaction studies have been conducted
- Potential for additive mobilization effects when used concurrently with other mobilizing agents such as plerixafor or G-CSF
Curated Content: Needs Vetting Before Put to Clinical Use